STLN
VENTE TOTALE: 298 853 titres (~1 946 310,05 $ US)
- Insiders
- Hively Brad
- Total bought
- —
- Total sold
- $1,946,310
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-27
STLN presents a critically weak financial foundation with negative operating margins, negative ROIC, and a debt-to-capital ratio exceeding 100%, making any bullish catalyst narrative extremely fragile.
The first sentence of the analysis written for STLN on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 |
|---|---|---|
| Gross Profit Margin | 15.2% | |
| Ebit Margin | -9.8% | |
| Ebitda Margin | -8.5% | |
| Operating Profit Margin | -7.2% | |
| Pretax Profit Margin | -12.1% | |
| Continuous Operations Profit Margin | -12.1% | |
| Net Profit Margin | -12.1% | |
| Bottom Line Profit Margin | -10.0% | |
| Current Ratio | 1.589 | |
| Quick Ratio | 1.351 | |
| Solvency Ratio | -0.298 | |
| Cash Ratio | 0.473 | |
| Price To Earnings Ratio | -10.741 | |
| Price To Earnings Growth Ratio | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.000 | |
| Price To Earnings Diluted Ratio | -10.741 | |
| Price To Earnings Diluted Growth Ratio | 0.000 | |
| Price To Book Ratio | -34.088 | |
| Price To Sales Ratio | 1.066 | |
| Price To Free Cash Flow Ratio | -19.285 | |
| Price To Operating Cash Flow Ratio | -21.794 | |
| Debt To Assets Ratio | 0.630 | |
| Debt To Equity Ratio | -6.596 | |
| Debt To Capital Ratio | 1.179 | |
| Long Term Debt To Capital Ratio | 1.255 | |
| Financial Leverage Ratio | -10.474 | |
| Working Capital Turnover Ratio | 0.000 | |
| Operating Cash Flow Ratio | -0.346 | |
| Operating Cash Flow Sales Ratio | -0.049 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.130 | |
| Debt Service Coverage Ratio | -3.759 | |
| Interest Coverage Ratio | -3.200 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.237 | |
| Capital Expenditure Coverage Ratio | -7.683 | |
| Dividend Paid And Capex Coverage Ratio | -7.683 | |
| Dividend Payout Ratio | 0.000 | |
| Enterprise Value Multiple | -14.253 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.2% | n/a | 0.0% |
| Ebit Margin | -9.8% | n/a | 0.0% |
| Ebitda Margin | -8.5% | n/a | 0.0% |
| Operating Profit Margin | -7.2% | n/a | 0.0% |
| Pretax Profit Margin | -12.1% | n/a | 0.0% |
| Continuous Operations Profit Margin | -12.1% | n/a | 0.0% |
| Net Profit Margin | -12.1% | n/a | 0.0% |
| Bottom Line Profit Margin | -10.0% | n/a | 0.0% |
| Current Ratio | 1.589 | n/a | 0.000 |
| Quick Ratio | 1.351 | n/a | 0.000 |
| Solvency Ratio | -0.297 | n/a | 0.000 |
| Cash Ratio | 0.473 | n/a | 0.000 |
| Price To Earnings Ratio | -10.741 | n/a | 0.000 |
| Price To Earnings Growth Ratio | 0.000 | n/a | 0.000 |
| Forward Price To Earnings Growth Ratio | 0.000 | n/a | 0.000 |
| Price To Earnings Diluted Ratio | -10.741 | n/a | 0.000 |
| Price To Earnings Diluted Growth Ratio | 0.000 | n/a | 0.000 |
| Price To Book Ratio | -34.088 | n/a | 0.000 |
| Price To Sales Ratio | 1.066 | n/a | 0.000 |
| Price To Free Cash Flow Ratio | -19.285 | n/a | 0.000 |
| Price To Operating Cash Flow Ratio | -21.794 | n/a | 0.000 |
| Debt To Assets Ratio | 0.630 | n/a | 0.000 |
| Debt To Equity Ratio | -6.596 | n/a | 0.000 |
| Debt To Capital Ratio | 1.179 | n/a | 0.000 |
| Long Term Debt To Capital Ratio | 1.255 | n/a | 0.000 |
| Financial Leverage Ratio | -10.474 | n/a | 0.000 |
| Working Capital Turnover Ratio | 0.000 | n/a | 0.000 |
| Operating Cash Flow Ratio | -0.346 | n/a | 0.000 |
| Operating Cash Flow Sales Ratio | -0.049 | n/a | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.130 | n/a | 0.000 |
| Debt Service Coverage Ratio | -3.759 | n/a | 0.000 |
| Interest Coverage Ratio | -3.200 | n/a | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | n/a | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.237 | n/a | 0.000 |
| Capital Expenditure Coverage Ratio | -7.683 | n/a | 0.000 |
| Dividend Paid And Capex Coverage Ratio | -7.683 | n/a | 0.000 |
| Dividend Payout Ratio | 0.000 | n/a | 0.000 |
| Enterprise Value Multiple | -14.253 | n/a | 0.000 |
Key metrics
| Metric | Trend | 2025 |
|---|---|---|
| Market cap | $535.9M | |
| Enterprise value | $606.0M | |
| EV / Sales | 1.21x | |
| EV / Op. cash flow | -24.65x | |
| EV / Free cash flow | -21.81x | |
| EV / EBITDA | -14.25x | |
| Net debt / EBITDA | -1.65x | |
| Current ratio | 1.59x | |
| Income quality | 0.41x | |
| Graham net-net | -$1 | |
| Tax burden | 99.8% | |
| Interest burden | 122.8% | |
| Working capital | $41.8M | |
| Invested capital | $93.1M | |
| Return on assets | -36.8% | |
| Operating ROA | 0.0% | |
| Return on tangible assets | -41.4% | |
| Return on equity | 385.5% | |
| Return on invested capital | -35.7% | |
| Return on capital employed | -38.5% | |
| Earnings yield | -11.3% | |
| Free cash flow yield | -5.2% | |
| Capex / Op. cash flow | -13.0% | |
| Capex / Depreciation | 46.1% | |
| Capex / Sales | 0.6% | |
| SG&A / Sales | 21.0% | |
| R&D / Sales | 0.0% | |
| Stock comp / Sales | 0.9% | |
| Intangibles / Total assets | 11.1% | |
| Days sales outstanding | 43d | |
| Days payables outstanding | 37d | |
| Operating cycle | 58d | |
| Cash conversion cycle | 21d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap 0.0%EV / Sales 0.0%EV / EBITDA 0.0%EV / Op. cash flow 0.000Earnings yield 0.000
Profitability
Return on equity 0.000Return on assets 0.000Return on invested capital 0.000Return on capital employed 0.000Operating ROA n/aIncome quality 0.000Tax burden 0.000
Efficiency
Days sales outstanding 0.000Days payables outstanding 0.000Operating cycle 0.000Cash conversion cycle 0.000Capex / Sales 0.000R&D / Sales n/a
Balance-sheet strength
Current ratio 0.000Net debt / EBITDA 0.000Working capital 0.000Invested capital 0.000Intangibles / Total assets 0.000
Change over 5 years
Valuation
Market cap 0.0%EV / Sales 0.0%EV / EBITDA 0.0%EV / Op. cash flow 0.000Earnings yield 0.000
Profitability
Return on equity 0.000Return on assets 0.000Return on invested capital 0.000Return on capital employed 0.000Operating ROA n/aIncome quality 0.000Tax burden 0.000
Efficiency
Days sales outstanding 0.000Days payables outstanding 0.000Operating cycle 0.000Cash conversion cycle 0.000Capex / Sales 0.000R&D / Sales n/a
Balance-sheet strength
Current ratio 0.000Net debt / EBITDA 0.000Working capital 0.000Invested capital 0.000Intangibles / Total assets 0.000
Employee count
No employee-count data synced.
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 Starling Oncology to Participate in Wells Fargo Healthcare Conference CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m.
- 2026-08-17 Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care''s persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.
- 2026-08-07 Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
- 2026-08-06 The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
- 2026-08-06 Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it''s full-year 2026 guidance.